In line with this, the assessment of mediators and biomarkers of cholesterol efflux, such as ABCG1, ABCA1, LCAT, and CETP, as well as indicators of cholesterol to bile acid conversion, such as CYP7A1, CYP8B1, specific oxysterols as intermediates, and bile acids themselves, should provide comprehensive insight into the changes in cholesterol homeostasis in MASLD. The gene discussed is LCAT; the disease is metabolic dysfunction-associated steatotic liver disease.